Search

Your search keyword '"Sill M."' showing total 266 results
Start Over Author "Sill M."
266 results on '"Sill M."'

2. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

Author

Mack, SC, Witt, H, Piro, RM, Gu, L, Zuyderduyn, S, Stütz, AM, Wang, X, Gallo, M, Garzia, L, Zayne, K, Zhang, X, Ramaswamy, V, Jäger, N, Jones, DTW, Sill, M, Pugh, TJ, Ryzhova, M, Wani, KM, Shih, DJH, Head, R, Remke, M, Bailey, SD, Zichner, T, Faria, CC, Barszczyk, M, Stark, S, Seker-Cin, H, Hutter, S, Johann, P, Bender, S, Hovestadt, V, Tzaridis, T, Dubuc, AM, Northcott, PA, Peacock, J, Bertrand, KC, Agnihotri, S, Cavalli, FMG, Clarke, I, Nethery-Brokx, K, Creasy, CL, Verma, SK, Koster, J, Wu, X, Yao, Y, Milde, T, Sin-Chan, P, Zuccaro, J, Lau, L, Pereira, S, Castelo-Branco, P, Hirst, M, Marra, MA, Roberts, SS, Fults, D, Massimi, L, Cho, YJ, Van Meter, T, Grajkowska, W, Lach, B, Kulozik, AE, von Deimling, A, Witt, O, Scherer, SW, Fan, X, Muraszko, KM, Kool, M, Pomeroy, SL, Gupta, N, Phillips, J, Huang, A, Tabori, U, Hawkins, C, Malkin, D, Kongkham, PN, Weiss, WA, Jabado, N, Rutka, JT, Bouffet, E, Korbel, JO, Lupien, M, Aldape, KD, Bader, GD, Eils, R, Lichter, P, Dirks, PB, Pfister, SM, Korshunov, A, and Taylor, MD

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Pediatric, Human Genome, Rare Diseases, Animals, Brain Neoplasms, CpG Islands, DNA Methylation, Embryonic Stem Cells, Ependymoma, Epigenesis, Genetic, Epigenomics, Female, Gene Expression Regulation, Neoplastic, Gene Silencing, Histones, Humans, Infant, Mice, Mice, Inbred NOD, Mice, SCID, Mutation, Phenotype, Polycomb Repressive Complex 2, Prognosis, Rhombencephalon, Xenograft Model Antitumor Assays, General Science & Technology
Abstract

Ependymomas are common childhood brain tumours that occur throughout the nervous system, but are most common in the paediatric hindbrain. Current standard therapy comprises surgery and radiation, but not cytotoxic chemotherapy as it does not further increase survival. Whole-genome and whole-exome sequencing of 47 hindbrain ependymomas reveals an extremely low mutation rate, and zero significant recurrent somatic single nucleotide variants. Although devoid of recurrent single nucleotide variants and focal copy number aberrations, poor-prognosis hindbrain ependymomas exhibit a CpG island methylator phenotype. Transcriptional silencing driven by CpG methylation converges exclusively on targets of the Polycomb repressive complex 2 which represses expression of differentiation genes through trimethylation of H3K27. CpG island methylator phenotype-positive hindbrain ependymomas are responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro and in vivo. We conclude that epigenetic modifiers are the first rational therapeutic candidates for this deadly malignancy, which is epigenetically deregulated but genetically bland.

Published
2014

3. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated

Author

Maas, SLN, Stichel, D, Hielscher, T, Sievers, P, Berghoff, AS, Schrimpf, D, Sill, M, Euskirchen, P, Blume, C, Patel, A, Dogan, H, Reuss, D, Dohmen, H, Stein, M, Reinhardt, A, Suwala, AK, Wefers, AK, Baumgarten, P, Ricklefs, F, Rushing, EJ, Bewerunge-Hudler, M, Ketter, R, Schittenhelm, J, Jaunmuktane, Z, Leu, S, Greenway, FEA, Bridges, LR, Jones, T, Grady, C, Serrano, J, Golfinos, J, Sen, C, Mawrin, C, Jungk, C, Hänggi, D, Westphal, M, Lamszus, K, Etminan, N, Jungwirth, G, Herold-Mende, C, Unterberg, A, Harter, PN, Wirsching, H-G, Neidert, MC, Ratliff, M, Platten, M, Snuderl, M, Aldape, KD, Brandner, S, Hench, J, Frank, S, Pfister, SM, Jones, DTW, Reifenberger, G, Acker, T, Wick, W, Weller, M, Preusser, M, von Deimling, A, Sahm, F, and German Consortium on Aggressive Meningiomas (KAM)

Abstract

PURPOSE: Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established (CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma. METHODS: DNA methylation data and copy-number information were generated for 3,031 meningiomas (2,868 patients), and mutation data for 858 samples. DNA methylation subgroups, copy-number variations (CNVs), mutations, and WHO grading were analyzed. Prediction power for outcome was assessed in a retrospective cohort of 514 patients, validated on a retrospective cohort of 184, and on a prospective cohort of 287 multicenter cases. RESULTS: Both CNV- and methylation family-based subgrouping independently resulted in increased prediction accuracy of risk of recurrence compared with the WHO classification (c-indexes WHO 2016, CNV, and methylation family 0.699, 0.706, and 0.721, respectively). Merging all risk stratification approaches into an integrated molecular-morphologic score resulted in further substantial increase in accuracy (c-index 0.744). This integrated score consistently provided superior accuracy in all three cohorts, significantly outperforming WHO grading (c-index difference P = .005). Besides the overall stratification advantage, the integrated score separates more precisely for risk of progression at the diagnostically challenging interface of WHO grade 1 and grade 2 tumors (hazard ratio 4.34 [2.48-7.57] and 3.34 [1.28-8.72] retrospective and prospective validation cohorts, respectively). CONCLUSION: Merging these layers of histologic and molecular data into an integrated, three-tiered score significantly improves the precision in meningioma stratification. Implementation into diagnostic routine informs clinical decision making for patients with meningioma on the basis of robust outcome prediction.

Published
2021

8. LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

Author

Eskander, R.N., Sill, M., Miller, A., Beffa, L., Moore, R., Hope, J., Musa, F., Mannel, R., Shahin, M.S., Canturia, G., Girda, E., Mathews, C., Kavecansky, J., Leath, C.A., III, Gien, L., Hinchcliff, E., Lele, S., Powell, M.A., and Aghajanian, C.

Published
2023
Full Text
View/download PDF

9. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Author

Alhalabi, K.T. Stichel, D. Sievers, P. Peterziel, H. Sommerkamp, A.C. Sturm, D. Wittmann, A. Sill, M. Jäger, N. Beck, P. Pajtler, K.W. Snuderl, M. Jour, G. Delorenzo, M. Martin, A.M. Levy, A. Dalvi, N. Hansford, J.R. Gottardo, N.G. Uro-Coste, E. Maurage, C.-A. Godfraind, C. Vandenbos, F. Pietsch, T. Kramm, C. Filippidou, M. Kattamis, A. Jones, C. Øra, I. Mikkelsen, T.S. Zapotocky, M. Sumerauer, D. Scheie, D. McCabe, M. Wesseling, P. Tops, B.B.J. Kranendonk, M.E.G. Karajannis, M.A. Bouvier, N. Papaemmanuil, E. Dohmen, H. Acker, T. von Hoff, K. Schmid, S. Miele, E. Filipski, K. Kitanovski, L. Krskova, L. Gojo, J. Haberler, C. Alvaro, F. Ecker, J. Selt, F. Milde, T. Witt, O. Oehme, I. Kool, M. von Deimling, A. Korshunov, A. Pfister, S.M. Sahm, F. Jones, D.T.W.

Abstract

Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens. © 2021, The Author(s).

Published
2021

10. A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study

Author

Bae-Jump, V.L., primary, Sill, M., additional, Gehrig, P.A., additional, Moxley, K., additional, Hagemann, A.R., additional, Waggoner, S.E., additional, O'Cearbhaill, R.E., additional, McDonald, M., additional, DiSilvestro, P.A., additional, Sperduto, P., additional, and Aghajanian, C., additional

Published
2020
Full Text
View/download PDF

11. Abstract B71: Molecular heterogeneity and novel oncogenic fusions in RELA- and YAP1-negative supratentorial ependymoma

Author

Ghasemi, D.R., primary, Okonechnikov, K., additional, Korshunov, A., additional, Sill, M., additional, Zheng, T., additional, Huebner, J.M., additional, Maass, K.K., additional, Benzel, J., additional, Snuderl, M., additional, Gojo, J., additional, Schüller, U., additional, Gerber, N.U., additional, Stoler, I., additional, Hernáiz-Driever, P., additional, Milde, T., additional, Sturm, D., additional, Chapman, R., additional, Grundy, R.G., additional, von Deimling, A., additional, Kawauchi, D., additional, Jones, D.T.W., additional, Kool, M., additional, Pfister, S.M., additional, Sahm, F., additional, and Pajtler, K.W., additional

Published
2020
Full Text
View/download PDF

12. Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14

Author

Deng, M. Y., primary, Sill, M., additional, Sturm, D., additional, Stichel, D., additional, Witt, H., additional, Ecker, J., additional, Wittmann, A., additional, Schittenhelm, J., additional, Ebinger, M., additional, Schuhmann, M. U., additional, Figarella‐Branger, D., additional, Aronica, E., additional, Staszewski, O., additional, Preusser, M., additional, Haberler, C., additional, Lauten, M., additional, Schüller, U., additional, Hartmann, C., additional, Snuderl, M., additional, Dunham, C., additional, Jabado, N., additional, Wesseling, P., additional, Deckert, M., additional, Keyvani, K., additional, Gottardo, N., additional, Giangaspero, F., additional, Hoff, K., additional, Ellison, D. W., additional, Pietsch, T., additional, Herold-Mende, C., additional, Milde, T., additional, Witt, O., additional, Kool, M., additional, Korshunov, A., additional, Wick, W., additional, Deimling, A., additional, Pfister, S. M., additional, Jones, D. T. W., additional, and Sahm, F., additional

Published
2020
Full Text
View/download PDF

13. Integrated molecular characterization of IDH -mutant glioblastomas

Author

Korshunov, A., primary, Casalini, B., additional, Chavez, L., additional, Hielscher, T., additional, Sill, M., additional, Ryzhova, M., additional, Sharma, T., additional, Schrimpf, D., additional, Stichel, D., additional, Capper, D., additional, Reuss, D. E., additional, Sturm, D., additional, Absalyamova, O., additional, Golanov, A., additional, Lambo, S., additional, Bewerunge-Hudler, M., additional, Lichter, P., additional, Herold-Mende, C., additional, Wick, W., additional, Pfister, S. M., additional, Kool, M., additional, Jones, D. T. W., additional, von Deimling, A., additional, and Sahm, F., additional

Published
2018
Full Text
View/download PDF

14. GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study

Author

Longoria, T.C., primary, Sill, M., additional, Monk, B.J., additional, Fruehauf, J., additional, Liao, S.Y., additional, Emerson, R., additional, Kim, J.H., additional, Mannel, R.S., additional, Lee, Y.C., additional, Mathews, C.A., additional, Randall, L.M., additional, Darcy, K.M., additional, Birrer, M.J., additional, and Tewari, K.S., additional

Published
2018
Full Text
View/download PDF

17. Payment For Designated Areas

Author

Webb, F. E., Barnett, B., Barnett, Ester R., Bruce-Smith, J., Colville, D. G., Cunningham, W., Frame, R. J., Lambert, N. G., Lines, L. M., Mattar, R. G., Redfern, E., Robinson, H. H., Sill, M. J., Wardle, A. D., Williams, L. R., and Witherow, J.

Published
1971

18. Papillary tumor of the pineal region: A distinct molecular entity

Author

Heim, S, Sill, M, Jones, DTW, Vasiljevic, A, Jouvet, A, Fèvre-Montange, M, Wesseling, P, Beschorner, R, Mittelbronn, M, Kohlhof, P, Hovestadt, V, Johann, P, Kool, M, Pajtler, KW, Korshunov, A, Ruland, V, Thomas, C, Witt, H, von Deimling, A, Paulus, W, Pfister, SM, Capper, D, and Hasselblatt, M

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Question: Papillary tumor of the pineal region (PTPR) is a neuroepithelial brain tumor which might pose diagnostic difficulties and recurs often. Little is known about underlying molecular alterations. Methods: Chromosomal copy number alterations (Affymetrix Oncoscan MIP SNP Array), DNA methylation[for full text, please go to the a.m. URL], 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

Published
2015
Full Text
View/download PDF

19. DNA methylation array-based molecular profiling for brain tumor classification

Author

Capper, D, Jones, DTW, Sill, M, Hovestadt, V, Schrimpf, D, Reuss, D, Sahm, F, Kölsche, C, Kratz, A, Mittelbronn, M, Schittenhelm, J, Olar, A, Buslei, R, Hartmann, C, Kohlhof, P, Hasselblatt, M, Schick, M, Bewerunge-Hudler, M, Korshunov, A, Aldape, K, von Deimling, A, and Pfister, SM

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Question/methods: Molecular technologies which can complement standard pathology testing have the potential to greatly enhance diagnostic precision. Analysis of DNA methylation, acting as a 'fingerprint' of cellular origin, is one such promising technology for tumor classification. We[for full text, please go to the a.m. URL], 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

Published
2015
Full Text
View/download PDF

21. Integrated molecular characterization of IDH‐mutant glioblastomas.

Author

Korshunov, A., Casalini, B., Chavez, L., Hielscher, T., Sill, M., Ryzhova, M., Sharma, T., Schrimpf, D., Stichel, D., Capper, D., Reuss, D. E., Sturm, D., Absalyamova, O., Golanov, A., Lambo, S., Bewerunge‐Hudler, M., Lichter, P., Herold‐Mende, C., Wick, W., and Pfister, S. M.

Subjects
GLIOBLASTOMA multiforme, ISOCITRATE dehydrogenase, DISEASE progression, DNA methylation, DNA fingerprinting
Abstract

Aims: Mutations of isocitrate dehydrogenase (IDH)1/2 affect almost all astrocytomas of WHO grade II and III. A subset of IDH‐mutant astrocytic tumours progresses to IDH‐mutant glioblastoma or presents with the histology of a glioblastoma at first presentation. We set out here to assess the molecular spectrum of IDH‐mutant glioblastomas. Methods: We performed an integrated molecular analysis of a mono‐centric cohort (n = 97); assessed through genome‐wide DNA methylation analysis, copy‐number profiling and targeted next generation sequencing using a neurooncology‐tailored gene panel. Results: Of these 97 IDH‐mutant glioblastomas, 68 had a glioblastoma at first presentation ('de novo' IDH‐mutant glioblastoma) and 29 emerged from a prior low‐grade lesion ('evolved' IDH‐mutant glioblastoma). Unsupervised hierarchical clustering of DNA methylation data disclosed that IDH‐mutant glioblastoma ('de novo' and 'evolved') formed a distinct group separate from other diffuse glioma subtypes. Homozygous deletions of CDKN2A/B were found to be associated with shorter survival. Conclusions: This study demonstrates DNA methylation patterns in IDH‐mutant glioblastoma to be distinct from lower‐grade astrocytic counterparts but homogeneous within de novo and evolved IDH‐mutant glioblastomas, and identifies CDKN2A as a marker for possible genetic sub‐stratification. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

22. O10.01PROGNOSTIC AND PREDICTIVE BIOMARKER-BASED SUBGROUPS IN THE NOA-04 TRIAL

Author

Wick W, Capper D, Sill M, Hovestadt V, Sm, Pfister, Michael Platten, Reifenberger G, von Deimling A, Weller M, and Wiestler B

Subjects
Cancer Research, Oncology, Oral Presentations, Neurology (clinical), neoplasms
Abstract

BACKGROUND: Molecular biomarkers, including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q codeletion, mutations and (consequently) loss of expression of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) and O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation, improve prognostication and may even guide treatment decisions in patients with anaplastic gliomas. Illumina Infinium HumanMethylation450 BeadChip arrays (HM450) allow the determination of large-scale methylation profiles and genome-wide DNA copy number changes, enabling molecular subgrouping of tumors. In addition, algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associated with IDH1/2 mutation, 1p/19q codeletion and MGMT promoter methylation using this assay. METHODS: In the biomarker cohort of the NOA-04 trial, the diagnostic and prognostic performance of these molecular markers using single tests, HM450 data and HM450-based algorithms has been investigated to propose biological subgroups, which reflect outcomes and potentially influence treatment decisions. RESULTS: Loss of ATRX expression was detected in 45% of anaplastic astrocytomas (AA), 27% of anaplastic oligoastrocytomas (AOA) and 10% of anaplastic oligodendrogliomas (AO). It was mostly restricted to IDH mutant tumors and almost mutually exclusive with 1p/19q co-deletion. In tumors with IDH1 mutation, MGMT promoter methylation was associated with prolonged progression-free survival (PFS) with chemotherapy or radiotherapy (RT), and thus prognostic. In tumors without IDH1 mutation, MGMT promoter methylation was associated with increased PFS in patients treated with chemotherapy, too, but not in those who received RT alone as the first-line treatment, and is thus chemotherapy-predictive. Comparisons of single assays and HM450-based algorithms revealed a high concordance for IDH and 1p/19q status. The HM450-derived MGMT-STP27 model to calculate MGMT promoter methylation probability revealed this aberration in a significantly higher fraction of cases as conventional methylation-specific PCR, with 87/91 G-CIMP-positive tumors predicted as MGMT promoter-methylated. CONCLUSIONS: ATRX loss is a hallmark and favorable prognosticator of astrocytic tumors allowing a better definition of the clinically and morphologically mixed group of AOA. MGMT promoter methylation is a predictive biomarker for benefit from alkylating agent chemotherapy in patients with IDH1-wildtype, but not IDH1-mutant malignant gliomas of WHO grades III/IV. Combined IDH1/ MGMT assessment may help to individualize clinical decision making in neurooncology. G-CIMP and 1p/19q codeletion are reliably detectable by HM450 analysis and associated with prognosis in the NOA-04 trial. HM450 arrays allowed clustering of anaplastic gliomas into relevant subgroups.

Published
2014

23. Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

Author

Westin, S.N., primary, Sill, M., additional, Coleman, R.L., additional, Waggoner, S.E., additional, Moore, K.N., additional, Mathews, C.A., additional, Jain, A., additional, Modesitt, S.C., additional, Schilder, R., additional, and Aghajanian, C., additional

Published
2016
Full Text
View/download PDF

24. A stratified randomized double-blind phase II trial of celecoxib in the treatment of patients with cervical intraepithelial neoplasia: A Gynecologic Oncology Group (GOG 0207) study with translational biomarkers and drug level monitoring

Author

Rader, J.S., primary, Sill, M., additional, Garcia, F., additional, Beumer, J.H., additional, Benbrook, D.M., additional, Zuna, R., additional, Spirtos, N.M., additional, Hamilton, C.A., additional, Lele, S.B., additional, Byron, J., additional, Alberts, D.S., additional, and Trimble, C., additional

Published
2016
Full Text
View/download PDF

25. GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer

Author

Cohn, D.E., primary, Sill, M., additional, Walker, J.L., additional, O'Malley, D.M., additional, Nagel, C.I., additional, Rutledge, T., additional, Bradley, W.H., additional, Richardson, D.L., additional, Moxley, K., additional, and Aghajanian, C., additional

Published
2016
Full Text
View/download PDF

26. NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results

Author

Matulonis, U.A., primary, Sill, M., additional, Thaker, P.H., additional, Carlson, J.W., additional, Darus, C.J., additional, Mannel, R.S., additional, Bender, D.P., additional, Higgins, R.V., additional, and Aghajanian, C., additional

Published
2016
Full Text
View/download PDF

27. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group (GOG) study

Author

Bender, D.P., primary, Sill, M., additional, Lankes, H., additional, Darus, C.J., additional, Delmore, J., additional, Rotmensch, J., additional, Gray, H.J., additional, Mannel, R.S., additional, Schilder, J.M., additional, Leslie, K.K., additional, Reyes, H.D., additional, Hunter, M., additional, McCourt, C.K., additional, and Samuelson, M., additional

Published
2015
Full Text
View/download PDF

29. EP-03 * MOLECULAR CLASSIFICATION OF EPENDYMAL TUMORS ACROSS ALL CNS COMPARTMENTS, HISTOPATHOLOGICAL GRADES AND AGE GROUPS

Author

Pajtler, K. W., primary, Witt, H., additional, Sill, M., additional, Jones, D., additional, Hovestadt, V., additional, Johann, P., additional, Reimand, J., additional, Lichter, P., additional, Taylor, M. D., additional, Gilbertson, R., additional, Ellison, D. W., additional, Aldape, K., additional, Korshunov, A., additional, Pfister, S. M., additional, and Kool, M., additional

Published
2015
Full Text
View/download PDF

30. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study

Author

Tewari, K.S., primary, Sill, M., additional, Monk, B.J., additional, Penson, R.T., additional, Lankes, H., additional, Leitao, M.M., additional, Ramondetta, L.M., additional, Van Le, L., additional, Richardson, D.L., additional, Landrum, L.M., additional, DiSilvestro, P.A., additional, Behbakht, K., additional, Ueland, F.R., additional, Michael, H., additional, and Birrer, M.J., additional

Published
2015
Full Text
View/download PDF

33. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial

Author

Wiestler, B., primary, Capper, D., additional, Hovestadt, V., additional, Sill, M., additional, Jones, D. T. W., additional, Hartmann, C., additional, Felsberg, J., additional, Platten, M., additional, Feiden, W., additional, Keyvani, K., additional, Pfister, S. M., additional, Wiestler, O. D., additional, Meyermann, R., additional, Reifenberger, G., additional, Pietsch, T., additional, von Deimling, A., additional, Weller, M., additional, and Wick, W., additional

Published
2014
Full Text
View/download PDF

34. PROGNOSTIC AND PREDICTIVE BIOMARKER-BASED SUBGROUPS IN THE NOA-04 TRIAL

Author

Wick, W., primary, Wiestler, B., additional, Capper, D., additional, Sill, M., additional, Hovestadt, V., additional, Schliesser, M. G., additional, Weiss, E., additional, Jones, D. T. W., additional, Roth, P., additional, Pfister, S. M., additional, Korshunov, A., additional, Platten, M., additional, Reifenberger, G., additional, von Deimling, A., additional, and Weller, M., additional

Published
2014
Full Text
View/download PDF

37. A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: A GOG study

Author

Alvarez, R.D., primary, Sill, M., additional, Davidson, S.A., additional, Muller, C., additional, Bender, D.P., additional, DeBernardo, R., additional, Behbakht, K., additional, and Huh, W.K., additional

Published
2014
Full Text
View/download PDF

38. TUMOUR BIOLOGY

Author

Geller, T., primary, Prakash, V., additional, Batanian, J., additional, Guzman, M., additional, Duncavage, E., additional, Gershon, T., additional, Crowther, A., additional, Wu, J., additional, Liu, H., additional, Fang, F., additional, Davis, I., additional, Tripolitsioti, D., additional, Ma, M., additional, Kumar, K., additional, Grahlert, J., additional, Egli, K., additional, Fiaschetti, G., additional, Shalaby, T., additional, Grotzer, M., additional, Baumgartner, M., additional, Braoudaki, M., additional, Lambrou, G. I., additional, Giannikou, K., additional, Millionis, V., additional, Papadodima, S. A., additional, Settas, N., additional, Sfakianos, G., additional, Stefanaki, K., additional, Kattamis, A., additional, Spiliopoulou, C. A., additional, Tzortzatou-Stathopoulou, F., additional, Kanavakis, E., additional, Gholamin, S., additional, Mitra, S., additional, Feroze, A., additional, Zhang, M., additional, Esparza, R., additional, Kahn, S., additional, Richard, C., additional, Achrol, A., additional, Volkmer, A., additional, Liu, J., additional, Volkmer, J., additional, Majeti, R., additional, Weissman, I., additional, Cheshier, S., additional, Bhatia, K., additional, Brown, N., additional, Teague, J., additional, Lo, P., additional, Challis, J., additional, Beshay, V., additional, Sullivan, M., additional, Mechinaud, F., additional, Hansford, J., additional, Arifin, M. Z., additional, Dahlan, R. H., additional, Sobana, M., additional, Saputra, P., additional, Tisell, M. T., additional, Danielsson, A., additional, Caren, H., additional, Bhardwaj, R., additional, Chakravadhanula, M., additional, Hampton, C., additional, Ozals, V., additional, Georges, J., additional, Decker, W., additional, Kodibagkar, V., additional, Nguyen, A., additional, Legrain, M., additional, Gaub, M. P., additional, Pencreach, E., additional, Chenard, M. P., additional, Guenot, D., additional, Entz-Werle, N., additional, Kanemura, Y., additional, Ichimura, K., additional, Shofuda, T., additional, Nishikawa, R., additional, Yamasaki, M., additional, Shibui, S., additional, Arai, H., additional, Xia, J., additional, Brian, A., additional, Prins, R., additional, Pennell, C., additional, Moertel, C., additional, Olin, M., additional, Bie, L., additional, Zhang, X., additional, Olsson, M., additional, Kling, T., additional, Nelander, S., additional, Biassoni, V., additional, Bongarzone, I., additional, Verderio, P., additional, Massimino, M., additional, Magni, R., additional, Pizzamiglio, S., additional, Ciniselli, C., additional, Taverna, E., additional, De Bortoli, M., additional, Luchini, A., additional, Liotta, L., additional, Barzano, E., additional, Spreafico, F., additional, Visse, E., additional, Sanden, E., additional, Darabi, A., additional, Siesjo, P., additional, Jackson, S., additional, Cohen, K., additional, Lin, D., additional, Burger, P., additional, Rodriguez, F., additional, Yao, X., additional, Liucheng, R., additional, Qin, L., additional, Na, T., additional, Meilin, W., additional, Zhengdong, Z., additional, Yongjun, F., additional, Pfeifer, S., additional, Nister, M., additional, de Stahl, T. D., additional, Basmaci, E., additional, Orphanidou-Vlachou, E., additional, Brundler, M.-A., additional, Sun, Y., additional, Davies, N., additional, Wilson, M., additional, Pan, X., additional, Arvanitis, T., additional, Grundy, R., additional, Peet, A., additional, Eden, C., additional, Ju, B., additional, Phoenix, T., additional, Nimmervoll, B., additional, Tong, Y., additional, Ellison, D., additional, Lessman, C., additional, Taylor, M., additional, Gilbertson, R., additional, Folgiero, V., additional, del Bufalo, F., additional, Carai, A., additional, Cefalo, M. G., additional, Citti, A., additional, Rutella, S., additional, Locatelli, F., additional, Mastronuzzi, A., additional, Maher, O., additional, Khatua, S., additional, Zaky, W., additional, Lourdusamy, A., additional, Meijer, L., additional, Layfield, R., additional, Jones, D. T. W., additional, Capper, D., additional, Sill, M., additional, Hovestadt, V., additional, Schweizer, L., additional, Lichter, P., additional, Zagzag, D., additional, Karajannis, M. A., additional, Aldape, K. D., additional, Korshunov, A., additional, von Deimling, A., additional, Pfister, S., additional, Chakrabarty, A., additional, Feltbower, R., additional, Sheridon, E., additional, Hassan, H., additional, Shires, M., additional, Picton, S., additional, Hatziagapiou, K., additional, Tsorteki, F., additional, Bethanis, K., additional, Gemou-Engesaeth, V., additional, Chi, S. N., additional, Bandopadhayay, P., additional, Janeway, K., additional, Pinches, N., additional, Malkin, H., additional, Kieran, M. W., additional, Manley, P. E., additional, Green, A., additional, Goumnerova, L., additional, Ramkissoon, S., additional, Harris, M. H., additional, Ligon, K. L., additional, Kahlert, U., additional, Suarez, M., additional, Maciaczyk, J., additional, Bar, E., additional, Eberhart, C., additional, Kenchappa, R., additional, Krishnan, N., additional, Forsyth, P., additional, McKenzie, B., additional, Pisklakova, A., additional, McFadden, G., additional, Pan, W., additional, Rodriguez, L., additional, Glod, J., additional, Levy, J. M., additional, Thompson, J., additional, Griesinger, A., additional, Amani, V., additional, Donson, A., additional, Birks, D., additional, Morgan, M., additional, Handler, M., additional, Foreman, N., additional, Thorburn, A., additional, Lulla, R. R., additional, Laskowski, J., additional, Fangusaro, J., additional, DiPatri, A. J., additional, Alden, T., additional, Tomita, T., additional, Vanin, E. F., additional, Goldman, S., additional, Soares, M. B., additional, Remke, M., additional, Ramaswamy, V., additional, Wang, X., additional, Jorgensen, F., additional, Morrissy, A. S., additional, Marra, M., additional, Packer, R., additional, Bouffet, E., additional, Jabado, N., additional, Cole, B., additional, Rudzinski, E., additional, Anderson, M., additional, Bloom, K., additional, Lee, A., additional, Leary, S., additional, Leprivier, G., additional, Rotblat, B., additional, Agnihotri, S., additional, Kool, M., additional, Derry, B., additional, Taylor, M. D., additional, Sorensen, P. H., additional, Dobson, T., additional, Busschers, E., additional, Taylor, H., additional, Hatcher, R., additional, Lulla, R., additional, Rajaram, V., additional, Das, C., additional, and Gopalakrishnan, V., additional

Published
2014
Full Text
View/download PDF

39. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

Author

Coleman, R.L., primary, Sill, M., additional, Aghajanian, C., additional, Gray, H.J., additional, Tewari, K.S., additional, Rubin, S.C., additional, Rutherford, T.J., additional, Chan, J.K., additional, Chen, H.X., additional, and Swisher, E.M., additional

Published
2014
Full Text
View/download PDF

40. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: A Gynecologic Oncology Group (GOG) study

Author

Tewari, K.S., primary, Sill, M., additional, Monk, B.J., additional, Long, H.J., additional, Penson, R.T., additional, Huang, H., additional, Landrum, L.M., additional, Oaknin, A., additional, Michael, H., additional, Moore, D.H., additional, Leitao, M.M., additional, Ramondetta, L.M., additional, and Reid, T.J., additional

Published
2014
Full Text
View/download PDF

41. EPENDYMOMA

Author

Hoffman, L. M., primary, Donson, A. M., additional, Nakachi, I., additional, Griesinger, A. M., additional, Birks, D. K., additional, Amani, V., additional, Hemenway, M. S., additional, Liu, A. K., additional, Wang, M., additional, Hankinson, T. C., additional, Handler, M. H., additional, Foreman, N. K., additional, Zakrzewska, M., additional, Zakrzewski, K., additional, Fendler, W., additional, Stefanczyk, L., additional, Liberski, P. P., additional, Massimino, M., additional, Gandola, L., additional, Ferroli, P., additional, Valentini, L., additional, Biassoni, V., additional, Garre, M. L., additional, Sardi, I., additional, Genitori, L., additional, Giussani, C., additional, Massimi, L., additional, Bertin, D., additional, Mussano, A., additional, Viscardi, E., additional, Modena, P., additional, Mastronuzzi, A., additional, Barra, S., additional, Scarzello, G., additional, Cinalli, G., additional, Peretta, P., additional, Giangaspero, F., additional, Boschetti, L., additional, Schiavello, E., additional, Calareso, G., additional, Antonelli, M., additional, Pecori, E., additional, Di Meco, F., additional, Migliorati, R., additional, Taborelli, A., additional, Witt, H., additional, Sill, M., additional, Wani, K., additional, Mack, S. C., additional, Capper, D., additional, Pajtler, K., additional, Lambert, S., additional, Tzaridis, T., additional, Milde, T., additional, Northcott, P. A., additional, Kulozik, A. E., additional, Witt, O., additional, Collins, V. P., additional, Ellison, D. W., additional, Taylor, M. D., additional, Kool, M., additional, Jones, D. T. W., additional, Korshunov, A., additional, Ken, A., additional, Pfister, S. M., additional, Makino, K., additional, Nakamura, H., additional, Kuroda, J.-i., additional, Kuratsu, J.-i., additional, Toledano, H., additional, Margolin, Y., additional, Ohali, A., additional, Michowiz, S., additional, Johann, P., additional, Tabori, U., additional, Walker, E., additional, Hawkins, C., additional, Taylor, M., additional, Yaniv, I., additional, Avigad, S., additional, Hoffman, L., additional, Plimpton, S. R., additional, Stence, N. V., additional, Vibhakar, R., additional, Lourdusamy, A., additional, Rahman, R., additional, Ward, J., additional, Rogers, H., additional, Grundy, R., additional, Punchihewa, C., additional, Lee, R., additional, Lin, T., additional, Orisme, W., additional, Dalton, J., additional, Aronica, E., additional, Smith, A., additional, Gajjar, A., additional, Onar, A., additional, Pounds, S., additional, Tatevossian, R., additional, Merchant, T., additional, Ellison, D., additional, Parker, M., additional, Mohankumar, K., additional, Weinlich, R., additional, Phoenix, T., additional, Thiruvenkatam, R., additional, White, E., additional, Gupta, K., additional, Boop, F., additional, Ding, L., additional, Mardis, E., additional, Wilson, R., additional, Downing, J., additional, Gilbertson, R., additional, Speed, D., additional, Gould, T., additional, Consortium, t. I. E., additional, Hoffman, L. M., additional, Griesinger, A., additional, Donson, A., additional, Birks, D., additional, Ohe, N., additional, Yano, H., additional, Nakayama, N., additional, Iwama, T., additional, Wright, K., additional, Hassall, T., additional, Bowers, D. C., additional, Crawford, J., additional, Bendel, A., additional, Fisher, P. G., additional, Klimo, P., additional, Armstrong, G., additional, Qaddoumi, I., additional, Robinson, G., additional, Wetmore, C., additional, Broniscer, A., additional, Chapman, R., additional, Mayne, C., additional, Duane, H., additional, Kilday, J.-P., additional, Coyle, B., additional, Graul-Conroy, A., additional, Hartsell, W., additional, Bragg, T., additional, Goldman, S., additional, Rebsamen, S., additional, Puccetti, D., additional, Salamat, S., additional, Patel, N. J., additional, Gomi, A., additional, Oguma, H., additional, Hayase, T., additional, Kawahara, Y., additional, Yagi, M., additional, Morimoto, A., additional, Wilbur, C., additional, Dunham, C., additional, Mabbott, D., additional, Carret, A.-S., additional, Lafay-Cousin, L., additional, McNeely, P. D., additional, Eisenstat, D., additional, Wilson, B., additional, Johnston, D., additional, Hukin, J., additional, Mynarek, M., additional, Kortmann, R. D., additional, Kaatsch, P., additional, Pietsch, T., additional, Timmermann, B., additional, Fleischhack, G., additional, Benesch, M., additional, Friedrich, C., additional, von Bueren, A. O., additional, Gerber, N. U., additional, Muller, K., additional, Tippelt, S., additional, Warmuth-Metz, M., additional, Rutkowski, S., additional, von Hoff, K., additional, Murugesan, M. K., additional, Poppleton, H., additional, Currle, S., additional, Kranenburg, T., additional, Eden, C., additional, Boulos, N., additional, Dapper, J., additional, Patel, Y., additional, Freeman, B., additional, Shelat, A., additional, Stewart, C., additional, Guy, R., additional, Adamski, J., additional, Huang, A., additional, Bartels, U., additional, Ramaswamy, V., additional, Krishnatry, R., additional, Laperriere, N., additional, Bouffet, E., additional, Araki, A., additional, Chocholous, M., additional, Gojo, J., additional, Dorfer, C., additional, Czech, T., additional, Dieckmann, K., additional, Slavc, I., additional, Haberler, C., additional, Doerner, E., additional, Muehlen, A. z., additional, Kortmann, R., additional, von Buehren, A., additional, Ottensmeier, H., additional, Resch, A., additional, Kwiecien, R., additional, Faldum, A., additional, Kuehl, J., additional, Sabnis, D., additional, Storer, L., additional, Simmonds, L., additional, Blackburn, S., additional, Lowe, J., additional, Kerr, I., additional, Wohlers, I., additional, Goschzik, T., additional, Dreschmann, V., additional, Denkhaus, D., additional, Rahmann, S., additional, Klein-Hitpass, L., additional, Iglesias, M. J. L., additional, Riet, F. G., additional, Dhermain, F. D., additional, Canale, S., additional, Dufour, C., additional, Rose, C. S., additional, Puget, S., additional, Grill, J., additional, Bolle, S., additional, Parkes, J., additional, Davidson, A., additional, Figaji, A., additional, Pillay, K., additional, Kilborn, T., additional, Padayachy, L., additional, Hendricks, M., additional, Van Eyssen, A., additional, Piccinin, E., additional, Lorenzetto, E., additional, Brenca, M., additional, Aldape, K., additional, Cho, Y.-J., additional, Weiss, W., additional, Phillips, J., additional, Jabado, N., additional, Mora, J., additional, Fan, X., additional, Jung, S., additional, Lee, J. Y., additional, Zitterbart, K., additional, French, P., additional, Kros, J. M., additional, Hauser, P., additional, Faria, C., additional, and Pfister, S., additional

Published
2014
Full Text
View/download PDF

42. High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study

Author

Tewari, K.S., primary, Sill, M., additional, Moore, D.H., additional, Long, H.J., additional, Penson, R.T., additional, Huang, H., additional, Landrum, L.M., additional, Oaknin, A., additional, Michael, H., additional, Monk, B.J., additional, Ramondetta, L.M., additional, Reid, T.J., additional, and Leitao, M.M., additional

Published
2014
Full Text
View/download PDF

43. Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study

Author

Tewari, K., primary, Sill, M., additional, Monk, B., additional, Long, H., additional, Ramondetta, L., additional, Landrum, L., additional, Oaknin, A., additional, Reid, T., additional, Leitao, M., additional, and Michael, H., additional

Published
2013
Full Text
View/download PDF

45. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

Author

Coleman, R., primary, Sill, M., additional, Aghajanian, C., additional, Gray, H., additional, Tewari, K., additional, Rubin, S., additional, Rutherford, T., additional, Chan, J., additional, and Swisher, E., additional

Published
2013
Full Text
View/download PDF

46. Identification of Two Molecular and Clinical Distinct Entities of Posterior Fossa Ependymoma

Author

Witt, H, primary, Mack, SC, additional, Ryzhova, M, additional, Bender, S, additional, Sill, M, additional, Isserlin, R, additional, Benner, A, additional, Hielscher, T, additional, Milde, T, additional, Remke, M, additional, Jones, DTW, additional, Northcott, PA, additional, Garzia, L, additional, Bertrand, KC, additional, Wittmann, A, additional, Deimling, A von, additional, Kulozik, AE, additional, Witt, O, additional, Bader, GD, additional, Rutka, JT, additional, Lichter, P, additional, Korshunov, A, additional, Taylor, MD, additional, and Pfister, SM, additional

Published
2011
Full Text
View/download PDF

47. A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) women with locally advanced cervical cancer (CXCA): A GOG study.

Author

Moore, K. N., primary, Sill, M., additional, Miller, D. S., additional, Disilvestro, P., additional, De Geest, K., additional, Rose, P. G., additional, Cardenes, H. R., additional, Mannel, R. S., additional, Farley, J. H., additional, Schilder, R. J., additional, and Fracasso, P. M., additional

Published
2011
Full Text
View/download PDF

49. Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial

Author

Chase, D., primary, Sill, M., additional, Chambers, M., additional, Darcy, K., additional, Han, E., additional, Fruehauf, J., additional, Monk, B., additional, Buening, B., additional, Sorosky, J., additional, and Burger, R., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results